Suven Life Sciences trades with traction on the bourses

19 Oct 2015 Evaluate

Suven Life Sciences is currently trading at Rs. 286.00, up by 2.35 points or 0.83% from its previous closing of Rs. 283.65 on the BSE.

The scrip opened at Rs. 286.70 and has touched a high and low of Rs. 288.50 and Rs. 282.35 respectively. So far 70697 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 338.50 on 15-Apr-2015 and a 52 week low of Rs. 177.60 on 17-Oct-2014.

Last one week high and low of the scrip stood at Rs. 295.90 and Rs. 275.80 respectively. The current market cap of the company is Rs. 3651.73 crore.

The promoters holding in the company stood at 59.57% while Institutions and Non-Institutions held 7.20% and 33.23% respectively.

Suven Life Sciences (Suven) will be participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) at SFN 2015 being held at Chicago, USA during October 17-21, 2015. Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 25 thousand Neuro-Scientists from all over the world covering the major Pharma, Biotech and Clinical Research institutes will be participating at this conference.

Key pharmacology, ADME, Safety and Phase-1 clinical data on SUVN-502 (5-HT6 receptor antagonist), SUVN-G3031 (Histamine-3 receptor antagonist), SUVN-D4010 (5-HT4 receptor partial agonist), CB2 agonist and Muscarinic (M1) acetylcholine receptor positive allosteric modulators (PAM) to treat the unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer’s, Schizophrenia, ADHD; Depression & Mood Disorders and Neuropathic Pain are being be presented by Suven scientists at SFN-2015. These data presentations highlight Suven’s continued commitment to explore new treatment options addressing unmet medical need through novel mechanisms and targets and address a market size of more than $35 billion.

During SFN-2015 Suven lined up several face to face meetings with major Pharma and Biotech companies to explore integrated collaborative research programs (CRP), Discovery and Development Support Services (DDDSS) and continued discussions with global pharma majors for potential partnering and out licensing of the clinical candidate SUVN-502.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

Suven Life Sciences Share Price

164.15 -6.00 (-3.53%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×